EUCTR2020-000504-11-SE进行中（未招募）1 期
Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 127
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •- Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- •- Diagnosis of congenital severe haemophilia A (FVIII less than 1%) or moderate/severe congenital haemophilia B (FIX equal to or less than 2%), or congenital haemophilia with inhibitors.
- •- For arm 1 only: Male aged less than <12 years of age at the time of signing informed consent.
- •- For arm 1 only: Patients with inhibitors (HAwI or HBwI):
- •a) Patients with HAwI with historical medical records of a total of at least 26 weeks of on-demand treatment within the last 52 weeks prior to
- •b) Patients with HBwI with historical medical records of a total of at least 26 weeks of on-demand treatment within the last 52 weeks prior to
- •c) Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment
- •- For arm 1 only: Patients without inhibitors (HA or HB):
- •a) Patients with historical medical records of at least 52 weeks of on-demand treatment during the last year prior to enrolment and with at
- •least 3 documented treated bleeds during this period
- •b) Patients with historical medical records of a total of at least 26 weeks of PPX treatment within the last 52 weeks prior to enrolment
- •- For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 125
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Known or suspected hypersensitivity to study intervention or related products.
- •- Known inherited or acquired coagulation disorder other than congenital haemophilia.
- •- Ongoing or planned Immune Tolerance Induction treatment.
- •- History of thromboembolic disease(a). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events(b)
- •(a) Includes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.
- •(b) Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events.
研究者
相似试验
招募中
1 期
A research study on how well concizumab works for you if you have haemophilia A or B with or without inhibitors (explorer10)CTIS2023-506925-13-00ovo Nordisk A/S135
进行中（未招募）
1 期
A research study on how well concizumab works for you if you have haemophilia A or B with or without inhibitors (explorer10)Haemophilia A with or without inhibitorsHaemophilia B with our without inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10053754Term: Hemophilia B without inhibitorsSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053753Term: Hemophilia A without inhibitorsSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850EUCTR2020-000504-11-ITOVO NORDISK. S.P.A.96
进行中（未招募）
1 期
A research study on how well concizumab works for you if you have haemophilia A or B with or without inhibitors (explorer10)Haemophilia A with or without inhibitorsHaemophilia B with our without inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10053753Term: Hemophilia A without inhibitorsSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10053754Term: Hemophilia B without inhibitorsSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-000504-11-BGovo Nordisk A/S127
招募中
3 期
Investigating efficacy, safety and pharmacokinetics ofconcizumab prophylaxis in children below 12 years with haemophilia A or B with or withoutinhibitorsJPRN-jRCT2031220097Shimizu Yu80
进行中（未招募）
1 期
A research study on how well concizumab works for you if you have haemophilia A or B with or without inhibitors (explorer10)EUCTR2020-000504-11-PLovo Nordisk A/S127